| Name | Title | Contact Details |
|---|
Icario is a health action company that frees you to help people live healthier lives by helping you connect with them like they`re human. With over 100 million+ member connections, Icario is a health action platform that unites pioneering technology, data science, and behavioral insights to connect everyone to better health. Our mission is to make the world a healthier place, one person at a time. In 2020, Revel + NovuHealth joined forces to create Icario because we knew we could do better together—creating value by uniting pioneering technology, data science, and behavioral insights to make the world a healthier place, one person at a time. There is an island in the Aegean Sea where people live extremely long lives. They`re happy, too. Families are close. They eat well. They exercise. And they stay connected with each other, and not just by smartphone. This got us thinking. What if we apply what we learn from the Blue Zone island of Ikaria (our namesake), add pioneering technology and exabytes of data, and help healthcare connect better with everyone? We`ll have a lot more healthy, happy people, and that`s a pretty good thing. As an organization, we`re a collaborative team of pioneers, inventors, and systems thinkers. We speak truth, are driven by data, and sweat the details. We`re a friendly and easygoing group, but we work hard because we are mission-driven, we know a better way, and we`re here to make it happen.
Webmedx is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients’ lives. We don’t think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.
LMA North America, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Keystone Medical Solutions is a Ada, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.